Dr. Mark Lebwohl graduated summa cum laude from Columbia College in 1974 and graduated from Harvard Medical School in 1978. He completed residencies in internal medicine and dermatology, both at Mount Sinai. Dr. Lebwohl has been practicing dermatology since 1983. He is professor and chairman of the Kimberly and Eric J. Waldman Department of Dermatology of the Icahn School of Medicine at Mount Sinai. Dr. Lebwohl is the President of the American Academy of Dermatology. Dr. Lebwohl is chairman emeritus of the medical board of the National Psoriasis Foundation. He is the founding editor of Psoriasis Forum, as well as a medical editor of the bulletin of the National Psoriasis Foundation, Psoriasis Advance. He is editor of the Dermatology Section of Scientific American Medicine. Dr. Lebwohl has chaired numerous symposia and has written, edited or co-edited several books including Psoriasis, Mild-to-Moderate Psoriasis and Moderate-to-Severe Psoriasis. He has authored or co-authored over 500 publications including peer-reviewed articles, invited articles and book chapters. Dr. Lebwohl is actively involved in clinical trials of many new dermatologic treatments.
Answers to Your Questions About Psoriasis
- Learn how to manage biologics in particular with infections
- Assess management of biologics in particular undergoing surgery
- Evaluate advantages/disadvantages of drug solutions
- New advances in dermatologic treatment
- Advances in medical knowledge
Bartelds, et al. JAMA. 2011;305:1460.
Den Broeder, et al; J Rheumatology. 2007;34:689.
2, 3, 6
Employer (Mount Sinai Medical Center) received research funding from: AbGenomics, AbbVie, Amgen, Anacor, Aqua, Canfite Biopharma, Celgene, Clinuvel, Coronado Biosciences, Ferdale, Lilly, Janssen Biotech, Leo Pharmaceuticals, Merz, Novartis, Pfizer, Sandoz, Valeant